13F filings
RA Capital Management
Where the disclosed book sits
by disclosed valueLargest holdings
20 of 84 positions| Holding | Type | Value | Shares | Share of book |
|---|---|---|---|---|
| ASNDAscendis Pharma A/S | Shares | $2.7B | 10,281,496 | 23.8% |
| PBLSParabilis Medicines Inc | Shares | $791.9M | 28,933,371 | 6.9% |
| RYTMRhythm Pharmaceuticals Inc | Shares | $740.2M | 6,666,837 | 6.4% |
| PCVXVaxcyte Inc | Shares | $667.0M | 11,474,599 | 5.8% |
| SIONSionna Therapeutics Inc | Shares | $435.7M | 9,905,045 | 3.8% |
| TYRATYRA Biosciences Inc | Shares | $389.6M | 12,198,625 | 3.4% |
| EWTXEdgewise Therapeutics Inc | Shares | $341.0M | 8,392,730 | 3% |
| NAMSNewamsterdam Pharma Co NV | Shares | $323.7M | 9,550,191 | 2.8% |
| COAGHemab Therapeutics Holdings | Shares | $286.8M | 7,808,627 | 2.5% |
| SEPNSepterna Inc | Shares | $234.3M | 6,995,858 | 2% |
| BCAXBicara Therapeutics Inc | Shares | $215.4M | 7,255,993 | 1.9% |
| MLYSMineralys Therapeutics Inc | Shares | $207.6M | 7,692,750 | 1.8% |
| GHRSGH Research PLC | Shares | $205.3M | 7,636,813 | 1.8% |
| IRONDISC Medicine Inc | Shares | $179.2M | 2,450,221 | 1.6% |
| SGPSpyglass Pharma Inc | Shares | $178.6M | 8,021,117 | 1.6% |
| ARTVArtiva Biotherapeutics Inc | Shares | $174.2M | 17,955,642 | 1.5% |
| JANXJanux Therapeutics Inc | Shares | $171.9M | 11,189,693 | 1.5% |
| TSHATaysha Gene Therapies Inc | Shares | $160.4M | 23,555,648 | 1.4% |
| BCRXBiocryst Pharmaceuticals Inc | Shares | $158.3M | 15,827,186 | 1.4% |
| WVEWAVE Life Sciences Ltd | Shares | $156.7M | 26,975,505 | 1.4% |
Share of book is the position's value against the whole disclosed 13F value, so the rows shown here do not sum to 100% unless every position is listed.
GetSignal pushes each new 13F to your phone as it is filed, with the positions that changed and the companies behind them. Free on iOS and Android.
What changed last quarter
15 largest moves| Holding | Move | Share change | Value change | Value after |
|---|---|---|---|---|
| ASNDASCENDIS PHARMA A/S | New | n/a | $2.7B | $2.7B |
| ASNDASCENDIS PHARMA A/S - ADR | Exited | n/a | -$2.4B | $0 |
| PBLSPARABILIS MEDICINES INC | New | n/a | $791.9M | $791.9M |
| COAGHEMAB THERAPEUTICS HOLDINGS | New | n/a | $286.8M | $286.8M |
| DNTHDIANTHUS THERAPEUTICS INC | Exited | n/a | -$219.2M | $0 |
| NUVLNUVALENT INC-A | Trimmed | -50.8% | -$159.0M | $153.9M |
| ABVXABIVAX SA-ADR | New | n/a | $150.9M | $150.9M |
| ORKAORUKA THERAPEUTICS INC | New | n/a | $148.0M | $148.0M |
| PRAXPRAXIS PRECISION MEDICINES I | Exited | n/a | -$120.4M | $0 |
| SRPTSAREPTA THERAPEUTICS INC | Exited | n/a | -$84.9M | $0 |
| EWTXEDGEWISE THERAPEUTICS INC | Trimmed | -19.5% | -$82.7M | $341.0M |
| SYRESPYRE THERAPEUTICS INC | Exited | n/a | -$81.8M | $0 |
| ARTVARTIVA BIOTHERAPEUTICS INC | Added | +82.2% | $78.6M | $174.2M |
| NTLAINTELLIA THERAPEUTICS INC | New | n/a | $76.6M | $76.6M |
| DFTXDEFINIUM THERAPEUTICS INC | New | n/a | $70.6M | $70.6M |
A change is this filing measured against the one before it. A 13F does not disclose trades, so the price paid and the day it happened are not in the record.
Questions
What does RA Capital Management hold?
RA Capital Management disclosed 84 positions worth $11.5B in the Q2 2026 13F filing. The largest is ASND at 23.8% of the disclosed book. A 13F lists long US equity positions only.
What did RA Capital Management buy and sell last quarter?
Comparing the Q2 2026 filing with the quarter before, the largest moves were New ASND, Exited ASND, New PBLS, New COAG. Changes are measured against the previous filing, not against trades, because a 13F does not disclose trades.
How current is this?
This is the Q2 2026 filing, covering positions held on Jun 30, 2026. A 13F is due 45 days after the quarter ends, so the most recent filing is always at least six weeks behind the market, and the manager may have changed the book since.
How to read a 13F
WHAT THE FILING COVERS
Positions are as disclosed to the SEC on Form 13F and are not investment advice. How this data is sourced, and what it cannot tell you, is on the methodology page.
Data as of Sep 10, 2026.